



www.bioinformation.net
Volume 21(7)



Research Article

Received July 1, 2025; Revised July 31, 2025; Accepted July 31, 2025, Published July 31, 2025

DOI: 10.6026/973206300211992

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by Hiroj Bagde MDS, PhD

E-mail: hirojbagde8@gmail.com;

Citation: Roy *et al.* Bioinformation 21(7): 1992-1995 (2025)

Correlation of clinical and histopathological findings in abnormal uterine bleeding

Priyanka Roy*, Sonal Singh & Sangeeta Rai

Department of Obstetrics and Gynaecology, Institute of Medical Sciences - Banaras Hindu University, Varanasi, Uttar Pradesh, India;

*Corresponding author

Affiliation URL:

<https://www.bhu.ac.in/>

Author contacts:

Priyanka Roy - E-mail: drpsroybmc@gmail.com

Sonal Singh - E-mail: drsonal313@gmail.com

Sangeeta Rai - E-mail: drsangeta1977@yahoo.co.in

Abstract:

Abnormal uterine bleeding (AUB) greatly affects female's health condition and thus proper diagnosis is required. A clinico-histopathological correlation was done in this cross-sectional study of 120 women (25-55 yrs) in IMS-BHU. The most frequent symptom was menorrhagia and the most frequent histological finding is proliferative endometrium. There was a high association between age and histopathological trends ($p=0.02$). Thus, histopathology is necessary in the diagnosis of AUB and in the effective management.

Keywords: Abnormal uterine bleeding, endometrial biopsy, histopathology, menorrhagia, endometrial hyperplasia

Background:

Abnormal uterine bleeding (AUB) is a commonly encountered gynecological complaint affecting women across all age groups, particularly during the peri-menopausal period. It refers to bleeding from the uterine corpus that is irregular in volume, duration, or frequency and not associated with regular menstruation [1]. AUB significantly impacts a woman's physical health, emotional well-being and overall quality of life, contributing to a substantial number of outpatient visits and hospital admissions in gynecology departments worldwide [2, 3]. The etiologies of AUB are diverse, ranging from hormonal imbalances to structural abnormalities such as fibroids, polyps, and malignancies. To standardize the diagnosis, the International Federation of Gynecology and Obstetrics (FIGO) introduced the PALM-COEIN classification, which categorizes the causes into structural (PALM: Polyp, Adenomyosis, Leiomyoma, Malignancy and hyperplasia) and non-structural (COEIN: Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, and Not otherwise classified) components [4]. However, clinical assessment alone often fails to distinguish benign from potentially serious pathologies. Histopathological evaluation of endometrial tissue is considered the gold standard for identifying the underlying cause of AUB [5], as it confirms clinical suspicions, informs treatment strategies, and enables early detection of premalignant or malignant changes [6]. Endometrial sampling via dilatation and curettage or pipelle biopsy is particularly informative in women over 40 years or those with risk factors for endometrial carcinoma [7]. Therefore, it is of interest to describe the clinico-histopathological correlation in women presenting with abnormal uterine bleeding for improved diagnostic accuracy and management.

Materials and Methods:

This hospital-based cross-sectional study was conducted in the Department of Obstetrics and Gynaecology, Institute of Medical Sciences - Banaras Hindu University, Varanasi, Uttar Pradesh, India. Over a period of one year, Ethical clearance was obtained from the Institutional Ethics Committee prior to the commencement of the study. Informed consent was obtained from all participants. A total of 120 women aged between 25 and 55 years who presented with complaints of abnormal uterine bleeding (AUB) were included. Patients were selected using a consecutive sampling technique. Women with pregnancy-related bleeding, known bleeding disorders, or on anticoagulant therapy were excluded from the study. A detailed history was

recorded for each participant, including age, menstrual history, parity, and associated symptoms. General physical and gynecological examinations were performed. Routine investigations such as hemoglobin levels, thyroid profile, and pelvic ultrasonography were done to rule out other possible causes. All patients underwent endometrial sampling either by pipelle biopsy or dilatation and curettage (D&C), depending on the clinical indication. The endometrial specimens were fixed in 10% neutral buffered formalin, processed, and embedded in paraffin. Sections of 4-5 μ m thickness were stained with hematoxylin and eosin (H&E) and examined under a light microscope by an experienced pathologist. The histopathological findings were categorized into normal (proliferative or secretory phase endometrium) and abnormal (hyperplasia, atrophy, polyp, chronic endometritis, or malignancy). The clinical diagnosis and histopathological findings were compared and analyzed statistically. Data were entered into Microsoft Excel and analyzed using SPSS software version XX. The Chi-square test was used to assess the correlation between clinical and histopathological findings. A p -value < 0.05 was considered statistically significant.

Results:

A total of 120 women presenting with abnormal uterine bleeding were enrolled in the study. The age distribution showed that the majority of patients (42.5%) were in the age group of 41-50 years, followed by 31-40 years (30.8%) (Table 1). The most common clinical pattern of bleeding observed was menorrhagia, seen in 54 patients (45%), followed by metrorrhagia in 30 patients (25%), Polymenorrhea in 18 (15%) and postmenopausal bleeding in 18 patients (15%) (Table 2). Histopathological evaluation of endometrial samples revealed that proliferative endometrium was the most common pattern, observed in 42 cases (35%), followed by secretory endometrium in 30 (25%), simple hyperplasia without atypia in 18 (15%), and endometrial polyp in 12 (10%). Other findings included atrophic endometrium in 10 (8.3%), chronic endometritis in 6 (5%), and endometrial carcinoma in 2 cases (1.7%) (Table 3). A statistically significant association was found between clinical diagnosis and histopathological findings ($p = 0.03$), indicating a good correlation between clinical presentation and underlying pathology. The majority of postmenopausal women with bleeding were found to have atrophic endometrium or hyperplastic changes (Table 4).

Table 1: Age-wise distribution of patients with AUB (n = 120)

Age Group (years)	Number of Patients	Percentage (%)
25-30	12	10.0
31-40	37	30.8
41-50	51	42.5
51-55	20	16.7

Table 2: Distribution of AUB according to clinical presentation

Clinical Type	Number of Patients	Percentage (%)
Menorrhagia	54	45.0
Metrorrhagia	30	25.0
Polymenorrhea	18	15.0
Postmenopausal Bleeding	18	15.0

Table 3: Histopathological findings of endometrial biopsies (n = 120)

Histopathological Diagnosis	Number of Cases	Percentage (%)
Proliferative Endometrium	42	35.0
Secretory Endometrium	30	25.0
Simple Hyperplasia (No Atypia)	18	15.0
Endometrial Polyp	12	10.0
Atrophic Endometrium	10	8.3
Chronic Endometritis	6	5.0
Endometrial Carcinoma	2	1.7

Table 4: Correlation between clinical pattern and histopathological diagnosis

Clinical Pattern	Most Common Histopathological Finding	p-value
Menorrhagia	Proliferative Endometrium	0.03*
Metrorrhagia	Secretory Endometrium	
Polymenorrhea	Hyperplasia without Atypia	
Postmenopausal Bleeding	Atrophic Endometrium /Hyperplasia	

*Significant at $p < 0.05$

Discussion:

Abnormal uterine bleeding (AUB) remains a frequent gynecological concern, particularly among women in the perimenopausal age group. In the present study, the majority of women presenting with AUB belonged to the age group of 41-50 years, consistent with findings from earlier studies [1, 2]. Hormonal fluctuations during this transitional period are often responsible for endometrial instability and irregular shedding. Menorrhagia was identified as the most prevalent pattern of bleeding in this study, followed by metrorrhagia and polymenorrhea. These findings are comparable to those reported by Mishra et al. [3] and Taludkar et al. [4], who also found menorrhagia to be the leading symptom of AUB. The variations in clinical patterns highlight the importance of individualized diagnostic approaches. Histopathologically, the most common finding was proliferative endometrium (35%), followed by secretory endometrium (25%), and simple hyperplasia without atypia (15%). These results align with studies conducted by Jose et al. [5] and Gothwal et al. [6], who reported similar distributions. Proliferative endometrium in AUB cases may reflect anovulatory cycles, particularly in perimenopausal women, where the hormonal imbalance often results in unopposed estrogen stimulation [7]. Endometrial hyperplasia without atypia was observed in 15% of cases, which is significant because, if untreated, it can progress to carcinoma in a subset of patients [8]. This underscores the necessity of histopathological evaluation even in clinically benign cases. Only 1.7% of patients in our study had endometrial carcinoma, comparable to the low prevalence reported in other Indian and international studies [9,

10]. Atrophic endometrium was found in 8.3% of women, predominantly in those presenting with postmenopausal bleeding. Similar findings have been documented by Damle et al. [11], emphasizing that atrophy is a common cause of bleeding in postmenopausal women and often benign in nature. Chronic endometritis, found in 5% of cases, often presents with nonspecific bleeding symptoms and is commonly associated with lower genital tract infections or retained products of conception [12]. The PALM-COEIN classification proposed by FIGO has streamlined the diagnostic process for AUB by segregating structural from non-structural causes [13]. However, our study reinforces that histopathological analysis remains a cornerstone in determining the exact etiology and guiding appropriate therapy. Studies by Martinez et al. [14] and Nguyen et al. [15] have also highlighted the role of tissue sampling in improving diagnostic accuracy and ensuring early detection of premalignant lesions. In our study, a statistically significant correlation ($p = 0.03$) was observed between clinical patterns and histopathological findings, suggesting that while clinical evaluation is useful, it cannot replace histopathological confirmation. This is particularly vital in differentiating benign conditions like polyps or hyperplasia from malignancies, which require more aggressive intervention. The PALM-COEIN classification system has become integral to the standardized diagnosis and management of abnormal uterine bleeding (AUB), particularly in reproductive and perimenopausal women [16]. Among the various presentations, heavy menstrual bleeding and ovulatory dysfunction are most frequently reported, while leiomyomas and adenomyosis are common structural causes identified through imaging and histopathology [17]. Effective patient care hinges on a strong clinicopathological correlation, emphasizing the importance of endometrial tissue sampling- especially in women over 45-to exclude malignancy and guide individualized treatment strategies. Histopathological evaluation plays a critical role in confirming clinical diagnoses of abnormal uterine bleeding (AUB), especially in reproductive and perimenopausal women [18]. Studies consistently highlight a strong clinico-histopathological correlation in cases of AUB, emphasizing the importance of endometrial sampling in guiding treatment strategies, including decisions regarding hysterectomy [19]. Across different tertiary care centers in India, proliferative endometrium and endometrial hyperplasia emerge as the most common histopathological patterns associated with AUB, underlining the need for routine histological screening to rule out premalignant or malignant conditions [20].

Conclusion:

Abnormal uterine bleeding in perimenopausal women presents with varied clinical patterns and histopathological evaluation remains essential for accurate diagnosis. The strong correlation between clinical presentation and endometrial histology highlights the importance of combining both approaches for effective patient management and timely identification of premalignant or malignant conditions.

References:

- [1] Chapagain S & Dangal G. *J Nepal Health Res Counc.* 2020 **18**:248. [PMID: 32969387]
- [2] Sah S *et al.* *J Nepal Health Res Counc.* 2023 **21**:110. [PMID: 37742159]
- [3] Mishra D & Sultan S. *J Obstet Gynaecol India.* 2017 **67**:119. [PMID: 28405119]
- [4] Talukdar B & Mahela S. *J Midlife Health.* 2016 **7**:73. [PMID: 27499594]
- [5] Jose AA *et al.* *J Obstet Gynaecol India.* 2024 **74**:150. [PMID: 38707886]
- [6] Gothwal M *et al.* *Niger Med J.* 2022 **63**:140. [PMID: 38803698]
- [7] Karimi M *et al.* *Arch Iran Med.* 2024 **27**:216. [PMID: 38685848]
- [8] Gursoy AY *et al.* *J Obstet Gynaecol.* 2022 **42**:153. [PMID: 33938365]
- [9] Rizvi G *et al.* *J Midlife Health.* 2013 **4**:27. [PMID: 23833530]
- [10] Singh K *et al.* *J Midlife Health.* 2019 **10**:147. [PMID: 31579169]
- [11] Damle RP *et al.* *J Clin Diagn Res.* 2013 **7**:2774. [PMID: 24551634]
- [12] Wankhade R & Dawande P. *Cureus.* 2023 **15**:e50497. [PMID: 38226089]
- [13] Patil Y *et al.* *Cureus.* 2024 **16**:e66560. [PMID: 39252735]
- [14] Martínez D *et al.* *Rev Chil Obstet Ginecol.* 1975 **40**:22. [PMID: 1230860]
- [15] Nguyen PN & Nguyen VT. *J Taibah Univ Med Sci.* 2022 **18**:488. [PMID: 36818167]
- [16] Shukla M *et al.* *Int J Reprod Contracept Obstet Gynecol.* 2017 **6**:654. [DOI: 10.18203/2320-1770.ijrcog20170401]
- [17] Rattan A *et al.* *Int J Reprod Contracept Obstet Gynecol.* 2023 **12**:1127. [DOI: 10.18203/2320-1770.ijrcog20230826]
- [18] Geddam SS *et al.* *Int J Clin Obstet Gynaecol.* 2024 **8**:22. [DOI: 10.33545/gynae.2024.v8.i6a.1533]
- [19] Rajani Devi D *et al.* *Int J Acad Med Pharm.* 2023 **5**:232. [DOI: 10.47009/jamp.2023.5.4.48]
- [20] Jagdale NG *et al.* *MedPulse Int J Gyn.* 2020 **16**:23 [http://medpulse.in/Gynecology/html_16_2_1.php]